Mettler-Toledo International (MTD US)
MTD US$1,737.26
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Share price activity
- Last (Price)
- 1,737.26
- Change
- ▲ 24.31 (1.42)
- Bid / Ask
- 0.00 - 0.00
- Volume
- 44,059
- Turnover
- 70,361,450
- Open
- 1,701.87
- Day Range
- 1,701.84 - 1,742.03
- VWAP
- 1,734.92
- Prev Close
- 1,712.95
- Last Trade
- 18/11 7:00pm
Key information
- Sector
- Healthcare
- Shares Issued
- 19,890,405
- NTA/Share
- -51.17
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
- Revenue
- 4,026.40
- EBITDA
- 1,243.03
- Profit
- 869.19
- Earnings Per Share (EPS)
- 42.05
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 34,554.80
- Price to Earnings Ratio (P/E)
- 37.71
Estimates (USD) · FY2027
- Revenue
- 4,419.79
- EBITDA
- 1,408.00
- Profit
- 1,008.92
- Earnings Per Share (EPS)
- 52.29
- Dividend Per Share (DPS)
- 0.00
Quantitative rating
Overvalued
- Economic Moat
- Narrow
- Financial Health
- Moderate
- Uncertainty
- High
Morningstar Quantitative Rating as of 18 NOV 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Five-star price 1,095.75 Fair value 1,351.44 One-star price 1,666.78
Morningstar Quantitative Rating as of 18 NOV 2026.
Quantitative valuation
- Fair Value
- 1,351.44
- Price / Fair Value
- 1.29
- Valuation
- Overvalued
- Uncertainty
- High
Morningstar Quantitative Rating as of 18 NOV 2026. The slider runs from the five-star price (1,095.75) to the one-star price (1,666.78).
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
| Price - closing or last bid | 1,712.95 |
| Price - 12 month high | 1,806.58 |
| Price - 12 month low | 1,023.28 |
| Pricing date | 17 NOV 2026 |
| Volume - avg. trading volume for the last ten days | 0.19 |
| Market capitalization | 34,554.80 |
| 12 Month High price date | 6 NOV 2026 |
| 12 Month Low price date | 13 MAY 2026 |
| Volume - avg. trading volume for the last 3 months | 0.20 |
| Price - 1 Day % Change | -0.83% |
| Price - 13 week price percent change | 20.85% |
| Price - 26 week price percent change | 66.04% |
| Price - 5 Day % Change | -2.19% |
| Price - 52 week price percent change | 23.33% |
| Price - YTD price percent change | 21.11% |
| Price % Change Month To Date | 5.59% |
| EPS excluding extraordinary items - most recent fiscal year | 42.050 |
| EPS excluding extraordinary items - trailing 12 month | 46.070 |
| EPS Normalized - most recent fiscal year | 42.730 |
| Revenue/share - most recent fiscal year | 194.778 |
| Revenue/share - trailing 12 month | 207.417 |
| Book value per share - most recent fiscal year | -1.161 |
| Book value per share - most recent quarter | 3.904 |
| Book value (tangible) per share - most recent fiscal year | -51.169 |
| Book value (tangible) per share - most recent quarter | -46.091 |
| Cash per share - most recent fiscal year | 3.285 |
| Cash per share - most recent quarter | 2.626 |
| Cash Flow per share - most recent fiscal year | 49.396 |
| Cash Flow per share - trailing 12 month | 54.440 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | 65.536 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 42.170 |
| EPS Basic excluding extraordinary items - trailing 12 month | 46.190 |
| EPS including extraordinary items - most recent fiscal year | 42.170 |
| EPS including extraordinary items - trailing 12 month | 46.240 |
| Free Cash Flow per share - trailing 12 month | 48.818 |
| P/E excluding extraordinary items, most recent fiscal year | 37.71 |
| P/E Normalized, most recent fiscal year | 37.55 |
| Price to sales - most recent fiscal year | 8.38 |
| Price to Tangible Book - most fiscal year | — |
| Price to Free Cash Flow per Share - most recent fiscal year | 35.59 |
| Price to Cash Flow per share - trailing 12 month | 31.91 |
| Price to Book - most recent fiscal year | 444.94 |
| P/E excluding extraordinary items high, trailing 12 months | 38.84 |
| P/E excluding extraordinary items low, trailing 12 months | 24.08 |
| Net Debt, LFI | 1,971.45 |
| Net Debt, LFY | 2,085.28 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
| Free Cash Flow - most recent fiscal year | 913.98 |
| LT debt/equity - most recent fiscal year | — |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | — |
| LT debt/equity - most recent quarter | 2,528.22% |
| Total debt/total equity - most recent quarter | 2,605.79% |
| Free Cash Flow - trailing 12 month | 988.16 |
| Payout ratio - trailing 12 month | — |
| Revenue - most recent fiscal year | 4,026.40 |
| Revenue - trailing 12 month | 4,198.47 |
| EBITD - most recent fiscal year | 1,243.03 |
| EBITD - trailing 12 month | 1,326.55 |
| Earnings before taxes - most recent fiscal year | 1,048.91 |
| Earnings before taxes - trailing 12 month | 1,128.33 |
| Net Income available to common - most recent fiscal year | 869.19 |
| Net Income available to common - trailing 12 months | 934.07 |
| Earnings before taxes Normalized - most recent fiscal year | 1,089.29 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 46.27 |
| Net Profit Margin % - 1st historical fiscal year | 21.59% |
| Net Profit Margin % - trailing 12 month | 22.25% |
| Operating margin - 1st historical fiscal year | 27.78% |
| Operating margin - trailing 12 month | 28.55% |
| Pretax margin - trailing 12 month | 26.87% |
| Pretax margin - 1st historical fiscal year | 26.05% |
| Operating Margin - 5 year average | 28.17% |
| Pretax Margin - 5 year average | 26.28% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 22.40% |
| Free Operating Cash Flow/Revenue, TTM | 23.54% |
| Net Profit Margin - 5 year average | 21.53% |
| Return on average assets - most recent fiscal year | 25.40% |
| Return on average assets - trailing 12 month | 25.56% |
| Return on average equity - most recent fiscal year | — |
| Return on average equity - trailing 12 month | — |
| Return on average assets - 5 year average | 25.11% |
| Return on average equity - 5 year average | — |
| Net Income/employee - most recent fiscal year | 52,361.02 |
| Revenue/employee - most recent fiscal year | 242,554.16 |
| Revenue growth rate, 5 year | 5.47% |
| EPS growth rate, 5 year | 11.04% |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | 8.85% |
| Growth rate% - Revenue, 3 year | 0.90% |
| Growth rate% - EPS, 3 year | 3.06% |
| Book value per share growth rate, 5 year | — |
| Capital Spending growth rate, 5 year | 2.98% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | 7.00% |
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.